Assessment of mimicking by EBV-CMV immunoglobulin M of anti-HLA antibodies

Basit Öğe Kaydı
dc.authoridGüleç, Rasime Derya/0000-0002-1534-7811
dc.authoridOzyilmaz, Berk/0000-0003-2654-3698
dc.authoridArslan, Fatma Demet/0000-0003-0766-0303
dc.authoridYilmaz Hanci, Sevgi/0000-0002-1198-5277
dc.authorwosidGüleç, Rasime Derya/HIR-9951-2022
dc.authorwosidOzkalay Yılmaz, Nisel/AAE-2293-2021
dc.authorwosidOzyilmaz, Berk/U-5685-2019
dc.authorwosidArslan, Fatma Demet/ABG-6885-2021
dc.contributor.authorGulec, Rasime Derya
dc.contributor.authorArslan, Fatma Demet
dc.contributor.authorOzyilmaz, Berk
dc.contributor.authorYilmaz, Nisel
dc.contributor.authorHanci, Sevgi Yilmaz
dc.contributor.authorKose, Sukran
dc.date.accessioned2024-03-09T18:48:21Z
dc.date.available2024-03-09T18:48:21Z
dc.date.issued2023
dc.departmentİzmir Bakırçay Üniversitesien_US
dc.description.abstractObjective: We aimed to show the cross-reactivity that may occur between immunoglobulin (Ig) M antibodies that form against Cytomegalovirus (CMV) and/or Epstein-Barr virus (EBV) and human leukocyte antigens (HLA).Methods: Complement-dependent cytotoxicity (CDC) cross-reactivity between serum samples of 57 patients with IgM positive CMV and/or EBV infections and T and B cells from 15 healthy donors were evaluated. Dithiothreitol was used to distinguish cross-reactivity caused by IgM antibodies from IgG.Results: The cross-reactivity ratio between pathogenic IgM antibodies with T cell of the 12th donor, and B cell of the 3rd, 4th, and 8th donors was significantly higher (p = 0.011, <0.001, <0.001 and 0.013, respectively). The ratio of B cell CDC cross-reactivity of all donors (26.4%) was higher than the ratio of T cell CDC cross-reactivity (5.2%) (p < 0.001). The ratio of T cell CDC cross-reactivity of sera containing both anti-CMV IgM and anti-EBV IgM antibodies was significantly higher than those of sera containing only anti-CMV IgM or only anti-EBV IgM antibodies (p = 0.002 and p < 0.001, respectively). There was no difference between B cell CDC cross-reactivity rates according to the presence of anti-CMV and/or anti-EBV IgM antibodies.Conclusion: Cross-reactivity may occur between anti-CMV and anti-EBV IgM antibodies with HLA molecules. Thus, in graft recipients, pathogenic IgMs can also act as de novo anti-HLA antibodies and aggravate the rejection process.en_US
dc.identifier.doi10.1016/j.jim.2023.113577
dc.identifier.issn0022-1759
dc.identifier.issn1872-7905
dc.identifier.pmid37865308en_US
dc.identifier.scopus2-s2.0-85175064397en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttps://doi.org/10.1016/j.jim.2023.113577
dc.identifier.urihttps://hdl.handle.net/20.500.14034/1305
dc.identifier.volume523en_US
dc.identifier.wosWOS:001107693800001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.ispartofJournal of Immunological Methodsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCytomegalovirus; Epstein-Barr Virus; Human Leukocyte Antigens; Complement Dependent Cytotoxicity; Cross-Reactivityen_US
dc.titleAssessment of mimicking by EBV-CMV immunoglobulin M of anti-HLA antibodiesen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
1305.pdf
Boyut:
409.77 KB
Biçim:
Adobe Portable Document Format
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu